Last edition
News about "The Indian Patent Office (IPO)"
India Revokes Patent for Novartis Cardiac Drug Vymada, Opens Door for Generics
The Indian Patent Office (IPO) has revoked the patent for Novartis’ cardiac drug Vymada—known globally as Entresto—on the grounds of lack of novelty and inventive step.
The Indian Patent Office (IPO) | 16/09/2025 | By Darshana | 110
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members